Skip to main content

Joint Pain Injections Market Report 2021-2028 | Size, Share, Growth, Trends, Revenue, Competitive Landscape, Analysis, Forecast

Top Players Covered in the Joint Pain Injections Market Research Report Are Anika Therapeutics, Inc., Teva Pharmaceuticals Industries Ltd., Flexion Therapeutics Inc., Pfizer Inc., Dr. Reddy’s Laboratories Ltd., Zimmer Biomet, Bioventus, SEIKAGAKU CORPORATION, ALLERGAN, and Ferring B.V. and other key market players.

Pune, India, July 29, 2021 (GLOBE NEWSWIRE) — Global Joint Pain Injections Market Size| 2021 Covid-19 Impact On Healthcare Industry Global Analysis By Size, Trends, Growth, Share, Business, Key Players, Merger, Statistics, Competitive Landscape, And Regional Forecast To 2026 is latest study published by Fortune Business Insights. CDC reports that every year approximately 15 million people in the U.S. face severe joint pain because of arthritis. The rising prevalence of arthritis can increase the demand for treatments, which in turn, will propel the growth of the global joint pain injections market.

One of the most common types of arthritis is osteoarthritis which primarily affects hands and feet. Some of the major causes associated with osteoarthritis are the rising prevalence of obesity, increasing aging population, zero physical activity, and mineral bone density loss.  Injections such as hyaluronic acid and corticosteroid are extensively used to reduce pain and inflammation in affected areas.  

Joint pains are more prevalent in the elderly population. As per research studies, injections such as platelet-rich plasma and placental tissue matrix have proved to be effective in the reduction of pain and inflammation. Furthermore, these infections will substantially reduce the risk of infection on the affected joint in the aged population. Driven by such factors, the joint pain injections market growth is likely to increase in the forthcoming years.


Request a Sample Copy of the Research Report: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/joint-pain-injections-market-100871

Some of the other players functioning in the global market are Anika Therapeutics, Inc., Teva Pharmaceuticals Industries Ltd., Flexion Therapeutics Inc., Pfizer Inc., Dr. Reddy’s Laboratories Ltd., Zimmer Biomet, Bioventus, SEIKAGAKU CORPORATION, ALLERGAN, and Ferring B.V.

Surging Research Investments to Give Significant Boost to the Market in North America

According to Arthritis Foundation, around 54 million people in the people suffer from arthritis and it is estimated that over 78 million people will be affected by this disease by 2040. This shows that the demand for joint pain medicine is likely to increase in the U.S., which drives the market in North America. As per the report, North America is anticipated to maintain its dominance in the global joint pain infections market through the forecast years. The growth is primarily attributable to the increasing prevalence of joint disorders.

People in this region are increasingly becoming aware of joint pain infections treatment. Not only this, leading players are making huge investments in research activities, which will eventually drive the market in North America. Several treatments such as knee arthritis viscosis supplementation received FDA approval, which contributes to the growth of the market in this region. Following North America, Europe is also expected to grow at a considerable rate in the forecast period.


Click here to get the short-term and long-term impact of COVID-19 on this Joint Pain Injections Market.

Please visit: https://www.fortunebusinessinsights.com/industry-reports/joint-pain-injections-market-100871

The market in Asia Pacific is expected to witness considerable growth owing to the rising prevalence of joint disorders and patient pool. Several government organizations are conducting awareness programs on different types of arthritis treatments available in the region. This will enhance the quality of life for such patients and augment demand for joint pain injections. Influenced by these factors, the joint pain infections market size is estimated to grow over the projected horizon.

SYNOJOYNT Receives FDA Approval

Joint pain injections are available for include hip, knee and ankle, shoulder and elbow joints. Of these, knee and ankle joints hold the largest share in the global market. This will surge the joint pain injections market size in the forthcoming years. These injections effectively reduce inflammation and pain in knees, thus increasing their demand.

“The increasing demand for cost-effective treatments and the rising prevalence of osteoarthritis are driving the joint pain injections market,” stated a lead analyst at Fortune Business Insights. These, coupled with rising technological advancements in healthcare, are likely to uplift the market growth. Several companies are introducing new products to strengthen their market position. SYNOJOYNT, a joint pain injection receives FDA approval for marketing this product. The injection was introduced by TEVA Pharmaceuticals in May 2018 for patients suffering from osteoarthritis. Zimmer Biomet develops a new joint pain injection containing hydraulic acid called Gel-One Hyaluronate. The injection received FDA approval in February 2017 and is used to treat patients with knee osteoarthritis.   


Quick Buy – Joint Pain Injections Market Research Report: https://www.fortunebusinessinsights.com/checkout-page/100871


Segmentation of the Global Joint Pain Injections Market

By Product           

  • Corticosteroid Injections
  • Hyaluronic Acid Injections
  • Platelet-Rich Plasma Injections
  • Others (Placental Tissue Matrix Injections, etc.)

By Joint Type        

  • Knee and Ankle
  • Hip
  • Shoulder and Elbow
  • Others

By Distribution Channel     

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Geography      

  • North America (the U.S. and Canada)
  • Europe (U.K., Germany, France, Italy, Spain, Scandinavia, and Rest of Europe)
  • Asia Pacific (Japan, China, India, Australia, Southeast Asia, and Rest of Asia Pacific)
  • Latin America (Brazil, Mexico, and Rest of Latin America)
  • Middle East & Africa (South Africa, GCC, and Rest of Middle East & Africa)


Get your Customized Research Report: https://www.fortunebusinessinsights.com/enquiry/customization/joint-pain-injections-market-100871


About Us:

Fortune Business Insights™ offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.

Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.

At Fortune Business Insights™ we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.


Contact Us:

Fortune Business Insights™ Pvt. Ltd.
308, Supreme Headquarters,
Survey No. 36, Baner,
Pune-Bangalore Highway,
Pune – 411045, Maharashtra, India.

Phone:
US :+1 424 253 0390
UK : +44 2071 939123
APAC : +91 744 740 1245
Email: sales@fortunebusinessinsights.com
Fortune Business Insights™
LinkedIn | Twitter | Blogs

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.